Augmentin Dosing for 6-Month-Old with Severe Respiratory Distress
For a 6-month-old infant with severe respiratory distress requiring hospitalization, use Augmentin ES-600 at 90 mg/kg/day (based on amoxicillin component) divided every 12 hours for 10 days. 1
Rationale for High-Dose Regimen
A 6-month-old with severe respiratory distress warrants hospitalization and aggressive antibiotic therapy. The high-dose formulation is critical because:
- Augmentin ES-600 provides 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate, specifically designed for resistant pathogens 1
- This dosing achieves plasma concentrations above the MIC for at least 34% of the dosing interval, which is necessary for efficacy against penicillin-resistant Streptococcus pneumoniae (MICs up to 4 mcg/mL) 2
- Standard-dose Augmentin (45 mg/kg/day) has only marginal efficacy against strains with penicillin MICs ≥4 mcg/mL 2
Specific Dosing Instructions
Weight-based dosing of Augmentin ES-600 (assuming typical 6-month-old weight of 7-8 kg):
- 8 kg infant: 3.0 mL twice daily
- 12 kg infant: 4.5 mL twice daily 1
Critical Formulation Warning
Do NOT substitute standard Augmentin suspensions (200 mg/5 mL or 400 mg/5 mL) for ES-600, as they contain different clavulanate ratios and are not interchangeable. ES-600 contains 42.9 mg clavulanate per 5 mL versus 28.5 mg or 57 mg in standard formulations 1
Clinical Context: Severe Respiratory Distress
For hospitalized infants with severe respiratory distress, the PIDS/IDSA guidelines recommend 3:
Parenteral therapy is preferred initially:
- Ampicillin 150-200 mg/kg/day IV every 6 hours, OR
- Ceftriaxone 50-100 mg/kg/day IV every 12-24 hours (preferred for high-level penicillin resistance or life-threatening infection)
Oral step-down therapy with Augmentin ES-600 is appropriate once:
- Clinical stability is achieved
- Ability to tolerate oral intake is confirmed
- No empyema or life-threatening complications exist
Pathogen Coverage Considerations
The high-dose regimen specifically targets:
- β-lactamase-producing Haemophilus influenzae: Augmentin (amoxicillin component 45-90 mg/kg/day) is the preferred oral agent 3
- Penicillin-resistant S. pneumoniae: High-dose amoxicillin (90 mg/kg/day) extends coverage to MICs of 4 mcg/mL 3
- Moraxella catarrhalis: Covered by the clavulanate component
Administration Guidelines
Optimize absorption and minimize GI intolerance 1:
- Administer at the start of a meal or snack
- Shake suspension vigorously before each dose
- Refrigerate reconstituted suspension; stable for 10 days
Common Pitfalls to Avoid
- Underdosing: Using standard 45 mg/kg/day dosing in severe infection or areas with resistant pneumococcus will result in treatment failure
- Wrong formulation: Substituting standard Augmentin for ES-600 provides inadequate amoxicillin dosing
- Premature oral switch: Ensure clinical stability before transitioning from IV to oral therapy in severe cases
- Ignoring local resistance patterns: If local epidemiology shows high-level penicillin resistance (MIC ≥4 mcg/mL), parenteral ceftriaxone is preferred over oral therapy 3
Safety Profile
In clinical trials of ES-600 in infants and children 1:
- Most common adverse events: vomiting (6.9%), fever (6.1%), diaper rash (6.1%), diarrhea (3.8%)
- Protocol-defined diarrhea occurred in 12.9% of patients
- Withdrawal rate due to diarrhea was minimal (2 patients out of hundreds)
- The twice-daily ES-600 regimen showed similar or lower adverse event rates compared to standard three-times-daily dosing 4
Duration of Therapy
10 days is the standard duration for community-acquired pneumonia in infants 1. Shorter courses are not recommended in this age group with severe disease.